1. Articles in category: Drug Development

    1-24 of 93 1 2 3 4 »
    1. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      J Control Release. 2018 Jul 03;285:162-171

      Authors: Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B

      Abstract High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment.

      Read Full Article
    2. Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma Interventions :   Drug: Vinblastine;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Nivolumab Sponsors :   Centre Oscar Lambret;   Anticancer Fund, Belgium;   Bristol-Myers Squibb Not yet recruiting

      Read Full Article
    3. Nanoparticles give immune cells a boost

      Nanoparticles give immune cells a boost

      ( Massachusetts Institute of Technology ) MIT researchers have devised a novel way to boost the effectiveness of T cell therapy against solid tumors. By attaching nanoparticle 'backpacks' carrying immune-stimulating drugs directly to T cells, the MIT engineers showed that they could enhance those T cells' response without inducing harmful side effects.

      Read Full Article
    4. New Model for Predicting Neuroblastoma Outcomes Incorporates Early Developmental Signals

      Motivated by a desire to better understand the molecular circuitry underlying neuroblastoma and limitations of current methods for predicting disease progression and outcome, researchers from the Kulesa Lab at the Stowers Institute for Medical Research and collaborators at the University of Michigan and Oxford University set out to construct a logic-based model incorporating information about developmental signaling pathways implicated in the disease.

      Read Full Article
      Mentions: ALK
    5. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search of novel therapeutic options. Here, we aimed at repurposing FDA-approved drugs for NB treatment by performing a high-content screening of a 349 anticancer compounds library.

      Read Full Article
      Mentions: Treatment
    6. New method to preserve boy cancer patient fertility being developed

      New method to preserve boy cancer patient fertility being developed

      Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center researchers in Beer-Sheva, Israel are developing a cell culture system that for the first time can change testicular stem cells into sperm-like cells that may enable future fertility for boys with prepubertal cancer.

      Read Full Article
      Mentions: Genetics
    7. Children with neuroblastoma have an elevated risk of long-term psychological difficulties

      A new study reveals that paediatric neuroblastoma patients are at elevated risk for long-term psychological impairment.

      In addition, those who experience such impairment as they get older tend to require special education services and to not go on to...

      Read Full Article
      Mentions: Treatment
    8. Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      J Cancer Stem Cell Res. 2017;5:

      Authors: Poniewierska-Baran A, Rajewska-Majchrzak J, Ratajczak MZ

      Abstract The erythropoietin receptor (EpoR) is expressed by cells from the erythroid lineage; however, evidence has accumulated that it is also expressed by some other non-hematopoietic tissues including several solid tumor cells and proposed candidates for cancer stem cells. This is an important concern, because recombinant erythropoietin (EPO) is frequently employed in cancer patients as a drug to ameliorate anemia related to chemo/radiotherapy. In our studies, we employed three human neuroblastoma ...

      Read Full Article
      Mentions: Radiotherapy
    9. miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      Biomed Pharmacother. 2018 Jul;103:1312-1318

      Authors: Wang X, Li J, Xu X, Zheng J, Li Q

      Abstract Although the treatment strategies for neuroblastoma (NB) develop rapidly, a considerable number of patients could not benefit from chemotherapy. Here, we revealed a miR-129-MYO10 axis that regulated neuroblastoma growth and chemosensitivity.

      Read Full Article
    10. Childhood cancer: The four survival strategies of tumor cells

      Childhood cancer: The four survival strategies of tumor cells

      ( Lund University ) Cancer cells in children tend to develop by following four main trajectories -- and two of them are linked to relapse of the disease, research led by Lund University in Sweden shows. The four strategies can occur simultaneously in a single tumor, according to the study that is now published in Nature Genetics.

      Read Full Article
      Mentions: Relapse Genetics
    11. New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

      New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

      CAMBRIDGE, Mass., June 2, 2018 /PRNewswire-USNewswire/ -- Why is it so hard to develop drugs for children with cancer? And what can be done about it? Those questions are central to a new study published today in JAMA Oncology that explores new business models for funding drug...

      Read Full Article
      Mentions: COG
    12. Emerging role of immunotherapy for childhood cancers.

      Emerging role of immunotherapy for childhood cancers.

      Chin Clin Oncol. 2018 Apr;7(2):14

      Authors: Handgretinger R, Schlegel P

      Abstract Recent developments in cell and gene therapy have a great impact on the new therapeutic approaches in pediatric cancers. Monoclonal antibodies for neuroblastoma and bispecific antibodies for leukemia have induced significant clinical responses for otherwise chemorefractory patients.

      Read Full Article
      Mentions: Immunotherapy
    13. Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Knockdown of zinc transporter ZIP8 expression inhibits neuroblastoma progression and metastasis in vitro.

      Mol Med Rep. 2018 May 02;:

      Authors: Mei Z, Yan P, Wang Y, Liu S, He F

      Abstract Neuroblastoma is one of the leading causes of cancer‑associated mortality worldwide, particularly in children, partially due to the absence of effective therapeutic targets and diagnostic biomarkers.

      Read Full Article
    14. A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy.

      Mol Cancer Ther. 2018 Apr 25;:

      Authors: Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L

      Read Full Article
    1-24 of 93 1 2 3 4 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles